Navigating the Trade-offs Between Systemic Orals and Biologic Injectables

Key Takeaways:

• According to Health Union’s PsA 2025 In America data, 60.5 percent of survey respondents currently use biologics, which are typically administered via injection, while 34.1 percent rely on non-biologic oral treatments.
• Biologics (specifically IL-17 and IL-23 inhibitors) remain the gold standard for inhibiting radiographic progression and managing severe skin or axial involvement, where orals may underperform or are not preferred.
• While biologics have a long-standing safety record, JAK inhibitors require rigorous screening for cardiovascular and thromboembolic risks in older patients with comorbidities such as smoking or diabetes.

The therapeutic landscape for psoriatic arthritis (PsA) has undergone a radical transformation over the last decade. While the traditional "step-up" approach – starting with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) before escalating to advanced therapies – remains a common framework, the arrival of highly targeted oral small molecules has complicated the decision-making process.^1,2

The choice between systemic orals and biologic injectables is no longer a simple matter of efficacy; it is a nuanced balancing act involving molecular precision, patient lifestyle, safety profiles, and the increasingly prominent role of shared decision-making.^1,2

The evolving role of conventional and targeted orals

Conventional orals, primarily methotrexate, remain the foundational therapy for many clinicians due to their long-term safety data and cost-effectiveness. However, their efficacy in axial disease and enthesitis is notably limited compared to advanced therapies. The real shift in the "oral" category has been the emergence of Janus kinase (JAK) inhibitors and phosphodiesterase-4 (PDE4) inhibitors.^1-4

• JAK inhibitors – These offer efficacy comparable to TNF inhibitors across multiple domains, including skin and joints. Recent data reinforce upadacitinib’s role in achieving high rates of ACR50/70 responses in patients who have failed prior biologics.
• PDE4 inhibitors – While these generally lack the "punch" of biologics for severe structural progression, their lack of required lab monitoring and favorable safety profile make it an attractive option for patients with moderate disease or those wary of immunosuppression. However, some patients cannot take this class of medications long-term due to severe stomach upset, nausea, or diarrhea, which limits their use in some cases.
• TYK2 inhibitors – The therapeutic ceiling for orals continues to rise with the introduction of selective tyrosine kinase 2 (TYK2) inhibitors. Late-breaking Phase 3 data from the POETIC-PsA 1 and 2 trials demonstrated that deucravacitinib achieved significantly higher ACR20 response rates than placebo at Week 24. Beyond joint efficacy, the data showed robust improvements in skin clearance and physical function, positioning TYK2 inhibition as a potent oral alternative to biologics for multi-domain disease.

Biologic injectables: The gold standard of precision

Biologic DMARDs targeting TNF, IL-17, or IL-23 remain the cornerstone for preventing structural damage. The primary trade-off here is the "administration burden" versus "molecular potency."^1,2,5

IL-17 and IL-23 inhibitors

These have largely overtaken TNF inhibitors for patients with significant skin involvement. Recent head-to-head data suggest that IL-17 inhibitors provide superior skin clearance while maintaining robust joint efficacy.^1,2,5

Structural preservation

For patients with aggressive, erosive disease, biologics offer the most robust evidence for slowing radiographic progression. The long half-lives of many injectables also allow for dosing schedules ranging from every 2 weeks to once every 3 months, which can paradoxically improve adherence compared to a daily pill.^1,2,5

The safety paradox and the "black box"

Perhaps the most significant trade-off currently facing clinicians is the safety profile of JAK inhibitors. Following the ORAL Surveillance study, the FDA and EMA have implemented warnings regarding the risk of major adverse cardiovascular events (MACE) and thromboembolism in high-risk patients.⁶

This necessitates a more rigorous screening process. A biologic might be the "safer" trade-off for an older patient with cardiovascular risk factors, whereas a JAK inhibitor might be the "preferred" trade-off for a younger, active patient who prioritizes the convenience of a pill and has no baseline risk.⁶

However, the emergence of highly selective TYK2 inhibitors may shift this risk-benefit calculation. By targeting the regulatory domain of TYK2 rather than the catalytic domains of JAK 1, 2, or 3, these molecules aim to avoid the off-target effects associated with MACE and VTE, providing a cleaner safety profile while maintaining oral convenience.⁴

Considering patient preference

This divergence in priorities is reflected in current utilization trends. Real-world data from Health Union’s PsA 2025 In America survey reveals a significant split in how patients manage their disease burden: 60.5 percent of survey respondents currently use biologics, which are typically administered via injection, while 34.1 percent rely on non-biologic oral treatments.^1,7

Some biologics are administered as infusions rather than injectables. Infusions may have better bioavailability and also better coverage by certain insurance plans, such as Medicare, which affects decision-making as well.

These figures underscore the importance of the shared decision-making process. Ultimately, these statistics remind clinicians that the "best" therapy on paper is only effective if it aligns with the patient's lived experience and willingness to adhere to the regimen.^1,7

Each patient will be different

Navigating the choice between systemic orals and biologic injectables requires the clinician to move beyond a "one-size-fits-all" algorithm. Biologics continue to lead in terms of long-term structural data and specific pathway targeting (especially IL-17/23 for skin). However, targeted orals offer a level of convenience and rapid onset that aligns with the modern patient’s lifestyle, provided the cardiovascular risk profile is managed.^1,2

Ultimately, the "best" therapy is the one the patient will consistently take and can tolerate without side effects. And in PsA, we are fortunate to have a toolkit that allows for that level of personalization.